Showing results (251-260 of 276) with videos related to

Sort By:
Pageof 28
Journal of the American College of Cardiology|July 14, 2001
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization NetworkP Kaul, Y Fu, W C Chang, et al.
The American Journal of Cardiology|June 15, 1992
Immediate and follow-up results of the conservative coronary angioplasty strategy for unstable angina pectorisF Stammen, I De Scheerder, J J Glazier, et al.
JAMA|March 3, 1999
Prognostic value of the admission electrocardiogram in acute coronary syndromesS Savonitto, D Ardissino, C B Granger, et al.
American Heart Journal|June 30, 2001
Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index: the GUSTO-I angiographic experienceC F Lundergan, A M Ross, W F McCarthy, et al.
Circulation|May 21, 1998
Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries TrialA M Ross, K S Coyne, E Moreyra, et al.
The Journal of Thoracic and Cardiovascular Surgery|January 26, 2006
Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgeryM Carrier, P Ménasché, J H Levy, et al.
Circulation|June 14, 2000
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14S A Coulter, C P Cannon, K A Ault, et al.
Circulation|October 15, 1995
A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial GroupS Vanderschueren, L Barrios, P Kerdsinchai, et al.
Circulation|January 25, 2000
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trialJ A de Lemos, E M Antman, C M Gibson, et al.
Quality & Safety in Health Care|August 13, 2010
Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curveJ M Taekman, M Stafford-Smith, E J Velazquez, et al.
Pageof 28